Crystal structure of the purine nucleoside phosphorylase (PNP) from Cellulomonas sp. and its implication for the mechanism of trimeric PNPs

Journal of Molecular Biology

Volumn 294, Issue 5, 1999, Pages 1239-1255

  Tebbe, Jan ^a   Bzowska, Agnieszka ^b   Wielgus Kutrowska, Beata ^b   Schröder, Werner ^a   Kazimierczuk, Zygmunt ^b   Shugar, David ^b   Saenger, Wolfram ^a   Koellner, Gertraud ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cellulomonas sp.; Mechanism; Purine nucleoside phosphorylase; Sequence; X ray crystallography

Indexed keywords

ARGININE; ASPARAGINE; GLUTAMIC ACID; GLYCINE; GUANINE; GUANOSINE; HISTIDINE; PHOSPHATE; PURINE NUCLEOSIDE PHOSPHORYLASE; SERINE;

ARTICLE; BETA SHEET; CELLULOMONAS; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME STRUCTURE; ENZYME SUBUNIT; ESCHERICHIA COLI; HYDROGEN BOND; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; SEQUENCE HOMOLOGY; SYNCHROTRON; X RAY CRYSTALLOGRAPHY;

EID: 0033579544     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1999.3327     Document Type: Article

References (84)

1. Brünger A. T. X-PLOR Version 3.1: A System for X-ray Crystallography and NMR. 1992a;Yale University Press, New Haven.
2. Brünger A. T. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature. 355:1992b;472-475.
3. Brünger A. T., Adams P. D., Clore G. M., DeLano W. L., Gros P., Grosse-Kunstleve R. W., Jiang J.-S., Kuszewski J., Nilges M., Pannu N., Read R. J., Rice L. M., Simonson T., Warren G. L. Crystallography & NMR systems: a new suite for macromolecular structure determination. Acta Crystallog. sect. D. 54:1998;905-921.
4. Bugg C. E., Carson W. M., Montgomery J. A. Drugs by design. Sci. Am. 269:1993;92-98.
5. Bzowska A., Kulikowska E., Darzynkiewcz E., Shugar D. Purine nucleoside phosphorylase. Structure-activity relationships for substrate and inhibitor properties of N-1-, N-7-, and C-8-substituted analogues: differentiation of mammalian and bacterial enzymes with N-1-methylinosine and guanosine. J. Biol. Chem. 263:1988;9212-9217.
6. Bzowska A., Kulikowska E., Shugar D. Properties of purine nucleoside phosphorylase (PNP) of mammalian and bacterial origin. Z. Naturforsch. sect. C. 45:1990;59-70.
7. Bzowska A., Kulikowska E., Shugar D., Bing-yi C., Lindborg B., Johansson N. G. Acyclonucleoside analogue inhibitors of mammalian purine nucleoside phosphorylase. Biochem. Pharmacol. 41:1991;1791-1803.
8. Bzowska A., Kulikowska E., Shugar D. Formycins A and B and some analogues: selective inhibitors of bacterial Escherichia coli purine nucleoside phosphorylase. Biochim. Biophys. Acta. 1120:1992;239-247.
9. Bzowska A., Ananiev A. V., Ramzaeva N., Alksins E., Maurins J. A., Kulikowska E., Shugar D. Purine nucleoside phosphorylase: inhibition by purine N(7)- and N(9)-acyclonucleosides; and substrate properties of 7-β-D-ribofuranosylguanine and 7-β-D-ribofuranosylhypoxanthine. Biochem. Pharmacol. 48:1994;937-947.
10. Bzowska A., Luic M., Schröder W., Shugar D., Saenger W., Koellner G. Calf spleen purine nucleoside phosphorylase: purification, sequence and crystal structure of its complex with an N(7)-acycloguanosine inhibitor. FEBS Letters. 367:1995;214-218.
11. Bzowska A., Kulikowska E., Poopeiko N. E., Shugar D. Kinetics of phosphorolysis of 3-(β-D-ribofuranosyl)adenine and 3-(β-D-ribofuranosyl)hypoxanthine, non-conventional substrates of purine-nucleoside phosphorylase. Eur. J. Biochem. 239:1996;229-234.
12. Bzowska A., Tebbe J., Wielgus-Kutrowska B., Schröder W., Shugar D., Saenger W., Koellner G. Crystallization and preliminary X-ray studies of purine nucleoside phosphorylase from Cellulomonas sp. Acta Crystallog. sect. D. 54:1998;1061-1063.
13. Carlson J. D., Fisher A. G. Thyroid purine nucleoside phosphorylase. II. Kinetic model by alternate substrate and inhibition studies. Biochim. Biophys. Acta. 566:1979;259-265.
14. Acta Crystallog. sect. D. 50:1994;760-763.
15. Cowtan K. dm: an automated procedure for phase improvement by density modification. Joint CCP4 and ESF-EACBM Newsletter on Protein Crystallography. 1994;. p. 34-38.
16. Daddona P. E., Wiesmann W. P., Milhouse W., Chern J.-W., Townsend L. B., Hershfield M. S., Webster H. K. Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. J. Biol. Chem. 261:1986;11667-11673.
17. Dawson R. M. C., Elliott D., Elliott W. H., Jones K. M. Data for Biochemical Research. 1969;Oxford University Press, London. p. 174-176.
18. Desiraju G. R., Steiner T. The Weak Hydrogen Bond in Structural Chemistry and Biology. 1999;Oxford University Press, Oxford.
19. Ealick S. E., Rule S. A., Carter D. C., Greenhough T. J., Babu Y. S., Cook W. J., Habash J., Helliwell J. R., Stoeckler J. D., Parks R. E. Jr, Chen S.-F., Bugg Ch. E. Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 Å resolution. J. Biol. Chem. 265:1990;1812-1820.
20. Erion M. D., Stoeckler J. D., Guida W. C., Walter R. L., Ealick S. E. Purine nucleoside phosphorylase. 2. Catalytic mechanism. Biochemistry. 36:1997;11735-11748.
21. Esnouf R. M. An extensively modified version of MOLSCRIPT that includes greatly enhanced colouring capabilities. J. Mol. Graph. 15:1997;132-134.
22. Fersht A. Enzyme Structure and Mechanism. 1984;Freeman and Company, New York.
23. Giblett E. R., Ammann A. J., Wara D. W., Sandman R., Diamond L. K. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1:1975;1010-1013.
24. Gros E., Witkop B. Selective cleavage of the methionyl peptide bonds in ribonuclease with cyanobromide. J. Am. Chem. Soc. 83:1961;1510-1511.
25. Guida W. C., Elliott R. D., Thomas H. J., Secrist J. A. III, Babu Y. S., Bugg C. E., Erion M. D., Ealick S. E., Montgomery J. A. Structure-based design of inhibitors of purine nucleoside phosphorylase. 4. A study of phosphate mimics. J. Med. Chem. 37:1994;1109-1114.
26. Halazy S., Ehrhard A., Danzin C. 9-(Difluorophosphonoalkyl)guanines as a new class of multisubstrate analogue inhibitors of purine nucleoside phosphorylase. J. Am. Chem. Soc. 113:1991;315-317.
27. Holmes R. E., Robins R. K. Purine nucleosides. VII. Direct bromination of adenosine, deoxyadenosine, guanosine, and related purine nucleosides. J. Am. Chem. Soc. 86:1964;1242-1245.
28. Hughes B. W., Wells A. H., Bebok Z., Gadi V. K., Garver R. I. Jr, Parker W. B., Sorscher E. J. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 55:1995;3339-3345.
29. Hutchinson E. G., Thornton J. M. PROMOTIF: a program to identify and analyze structural motifs in proteins. Protein Sci. 5:1996;212-220.
30. Iwata H., Wada Y., Walsh M., Montgomery J. A., Hirose H., Mendez R., Cicciarelli J., Iwaki Y. In vitro study of BCX-34: a new human T-lymphocyte-specific purine phosphorylase inhibitor. Transplant. Proc. 30:1998;983-986.
31. Jensen K. F. Purine nucleoside phosphorylase form Salmonella typhimurium and Escherichia coli. Initial velocity kinetics, ligand binding and reaction mechanism. Eur. J. Biochem. 61:1976;377-386.
32. Jones T. A., Zou J.-Y., Cowan S. W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors of these models. Acta Crystallog. sect. A. 47:1991;110-119.
33. Kalckar H. M. Differential spectrophotometry of purine compounds by means of specific enzymes. I. Determination of hydroxypurine compounds. J. Biol. Chem. 167:1947;429-443.
34. Keleti T. Basic Enzyme Kinetics. 1986;Akademiai Kiado, Budapest.
35. Kelley J. L., Linn J. A., McLean E. W., Tuttle J. V. 9-[(Phosphonoalkyl)benzyl]guanines. Multisubstrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase. J. Med. Chem. 36:1993;3455-3463.
36. Kelley J. L., McLean E. W., Crouch R. C., Averett D. R., Tuttle J. V. [(Guaninylalkyl)phosphinico]methyl]phosphonic acids. Multisubstrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase. J. Med. Chem. 38:1995;1005-1014.
37. Kierdaszuk B., Modrak-Wojcik A., Shugar D. Binding of phosphate and sulphate anions by purine nucleoside phosphorylase from E. coli: ligand-dependent quenching of enzyme intrinsic fluorescence. Biophys. Chem. 63:1997;107-118.
38. Kline P. C., Schramm V. L. Purine nucleoside phosphorylase. Inosine hydrolysis, tight binding of the hypoxanthine intermediate, and third-the-sites reactivity. Biochemistry. 31:1992;5964-5973.
39. Kline P. C., Schramm V. L. Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction. Biochemistry. 32:1993;13212-13219.
40. Kline P. C., Schramm V. L. Pre-steady-state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase. Biochemistry. 34:1995;1153-1162.
41. Koda R. T., Biles J. A., Wolf W. Synthesis of some iodopurine derivatives. J. Pharmacol. Sci. 57:1968;2056-2061.
42. Koellner G., Luic M., Shugar D., Saenger W., Bzowska A. Crystal structure of the calf spleen purine nucleoside phosphorylase in a complex with hypoxanthine at 2.15 Å resolution. J. Mol. Biol. 265:1997;202-216.
43. Koellner G., Luic M., Shugar D., Saenger W., Bzowska A. Crystal structure of the ternary complex of E. coli purine nucleoside phosphorylase with formycin B, a structural analogue of the substrate inosine, and phosphate (sulphate) at 2.1 Å resolution. J. Mol. Biol. 280:1998;153-166.
44. Kraulis P. J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallog. 24:1991;946-950.
45. Kulikowska E., Bzowska A., Wierzchowski J., Shugar D. Properties of two unusual and fluorescent substrates of purine nucleosides phosphorylase: 7-methylguanosine and 7-methylinosine. Biochim. Biophys. Acta. 874:1986;355-363.
46. Laskowski R. A., MacArthur M. W., Moss D. S., Thornton J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26:1993;283-291.
47. Leonard N. J., Laursen R. A. Synthesis of 3-(β-D-ribofuranosyl)adenine and 3-(β-D-ribofuranosyl) adenine-5′-phosphate. Biochemistry. 4:1965;354-365.
48. Lipkin D., Howard F. B., Nowotny D., Sano M. Iodination of nucleosides and nucleotides. J. Biol. Chem. 238:1963;PC2249-PC2253.
49. Luzzati V. Traitement statistique des erreurs dans la determination des structures cristallines. Acta Crystallog. 5:1952;802-810.
50. Mao C., Cook W. J., Zhou M., Koszalka G. W., Krenitsky T. A., Ealick S. E. The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology. Structure. 5:1997;1373-1383.
51. Mao C., Cook W. J., Zhou M., Federov A. A., Almo S. C., Ealick S. E. Calf spleen purine nucleoside phosphorylase complexed with substrates and substrate analogues. Biochemistry. 37:1998;7135-7146.
52. Matthews B. W. Solvent content of protein crystals. J. Mol. Biol. 33:1968;491-497.
53. Merritt E. A., Bacon D. J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277:1997;505-524.
54. Miles R. W., Tyler P. C., Furneaux R. H., Bagdassarian C. K., Schramm V. L. One third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry. 37:1998;8615-8621.
55. Miller R. L., Sabourin C. L., Krenitsky T. A. Trypanosoma cruzi adenine nucleoside phosphorylase. Purification and substrate specificity. Biochem. Pharmacol. 36:1987;553-560.
56. Minor W. XDISPLAYF Program. 1993;Purdue University.
57. Montgomery J. A. Purine nucleoside phosphorylase: a target for drug design. Med. Res. Rev. 13:1993;209-228.
58. Montgomery J. A., Niwas S., Rose J. D., Secrist J. A. III, Babu Y. S., Bugg C. E., Erion M. D., Guida W. C., Ealick S. E. Structure-based design of inhibitors of purine nucleoside phosphorylase. 1. 9-(arylmethyl) derivatives of 9-dazaguanine. J. Med. Chem. 36:1993;55-69.
59. Narayana S. V., Bugg C. E., Ealick S. E. Refined structure of purine nucleoside phosphorylase at 2.75 Å resolution. Acta Crystallog. sect. D. 53:1997;131-142.
60. Navazza J. AMoRe: an automated package for molecular replacement. Acta Crystallog. sect. B. 50:1994;157-163.
61. Otwinowski Z. Oscillation data reduction program. Sawyer L., Isaacs N., Bailey S. Proceedings of the CCP4 Study Weekend: Data Collection and Processing 29-30 January 1993. 1993;56-62.
62. Puhlmann M., Gnant M., Brwon C. K., Richard A., Bartlett D. L. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Human Gene Ther. 10:1999;649-657.
63. Read R. J. Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Crystallog. sect. A. 42:1986;140-149.
64. Richardson J. S. Protein taxonomy. Advan. Protein Chem. 34:1981;253-339.
65. Ropp A., Traut T. W. Purine nucleoside phosphorylase. Allosteric regulation of a dissociating enzyme. J. Biol. Chem. 266:1991;7682-7687.
66. Savage B., Spencer N. Rabbit erythrocyte purine nucleoside phosphorylase. Initial velocity studies. Biochem. J. 179:1979;21-27.
67. Secrist J. A. III, Niwas S., Rose J. D., Babu Y. S., Bugg C. E., Erion M. D., Guida W. C., Ealick S. E., Montgomery J. A. Structure-based design of inhibitors of purine nucleoside phosphorylase. 2. 9-Alicyclic and 9-heteroalicyclic derivatives of 9-deazaguanine. J. Med. Chem. 36:1993;1847-1854.
68. Schulz G. E., Schirmer R. H. Principles of Protein Structures. 1979;Springer-Verlag, Heidelberg.
69. Shugar D., Psoda A. Tautomerism of purines and pyrimidines, their nucleosides and various analogues. Landoldt-Börnstein. 1990;Springer-Verlag Heidelberg. p. 308-348.
70. Sircar J. C., Kostlan C. R., Gilbertsen R. B., Bennett M. K., Dong M. K., Cetenko W. J. Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2[d] pyrimidin-4-one. J. Med. Chem. 35:1992;1605-1609.
71. Sorscher E. J., Peng S., Bebok Z., Allan P. W., Bennett L. L. Jr, Parker W. B. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther. 1:1994;233-238.
72. Stoeckler J. D. Purine nucleoside phosphorylase: a target for chemotherapy. Glazer R. J. Developments in Cancer Chemotherapy. 1984;35-60 CRC Press Inc. Boca Raton.
73. Stoeckler J. D., Agarwal R. P., Agarwal K. C., Parks R. E. Jr. Purine nucleoside phosphorylase from human erythorcytes. Methods Enzymol. 51:1978;530-538.
74. Stoeckler J. D., Pirot A. F., Smith R. M., Parks R. E. Jr, Ealick S. E., Takabayashi K., Erion M. D. Purine nucleoside phosphorylase. 3. Reversal of purine base specificity by site-directed mutagenesis. Biochemistry. 36:1997;11749-11756.
75. Surette M., Gill T., MacLean S. Purification and characterization of purine nucleoside phosphorylase from Proteus vulgaris. Appl. Environ. Microbiol. 56:1990;1435-1439.
76. Tebbe J. Three-dimensional structure of purine nucleoside phosphorylase of Cellulomonas. PhD thesis. 1999;Freie Universität Berlin, Institut für Kristallographie.
77. Walter R. L., Symersky J., Poirot A. F., Stoeckler J., Erion M., Ealick S. E. X-ray crystallographic and kinetic analysis of human pur ine nucleoside phosphorylase complexes with 1-β-D-robofuranosyl-1,2,4-triazole-3-carboxamide and 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine. Nucleosides Nucleotides. 13:1994;689-706.
78. Wielgus-Kutrowska B. Purine nucleoside phosphorylase-physico-chemical properties and mechanism of interaction with ligands. PhD thesis. 1999;Department of Biophysics,Institute of Experimental Physics,University of Warsaw.
79. Wielgus-Kutrowska B., Kulikowska E., Wierzchowski J., Bzowska A., Shugar D. Nicotinamide riboside, an unusual, non-typical, substrate of purified purine nucleoside phosphorylases. Eur. J. Biochem. 243:1997;408-414.
80. Wielgus-Kutrowska B., Tebbe J., Schröder W., Luic M., Shugar D., Saenger W., Koellner G., Bzowska A. Cellulomonas sp. purine nucleoside phosphorylase: comparison with human and E. coli enzymes. Advan. Exp. Med. Biol. 431:1998;259-264.
81. Wielgus-Kutrowska B., Tebbe J., Wierzchowski J., Shugar D., Saenger W., Koellner G., Bzowska A. Binding of substrates by purine nucleoside phosphorylase from Cellulomonas sp. - kinetic and spectrofluorimetric studies. Nucleosides Nucleotides. 18:1999;875-876.
82. Yokomatsu T., Sato M., Abe H., Suemune K., Matsumoto K., Kihara T., Soeda T., Shimeno H., Shibuya S. Synthesis of (2′S, 3′S)-9-(4′-phosphono-4′,4′-difluoro-2′,3′- methanobutyl)guanine and its enantionmer. Evaluation of the inhibitory activity of purine nucleoside phosphorylase. Tetrahedron. 53:1997;11297-11306.
83. Yokomatsu T., Abe H., Sato M., Suemune K., Kohara T., Soeda T., Shimeno H., Shibuya S. Synthesis of 1,1-difluoro-5-(1H-9-purinyl)-2-pentenphosphonic acids and the related methano analogues. Remarkable effect of the nucleobases and the cyclopropane ring on inhibitory activity toward purine nucleoside phosphorylase. Bioorg. Med. Chem. 6:1998;2495-2505.
84. Zimmerman T. P., Gersten N. B., Ross A. F., Mech R. P. Adenine as a substrate for purine nucleoside phosphorylase. Can. J. Biochem. 49:1971;1050-1054.